However, in breast cancer, MEK inhibitors do not improve overall survival [30] One study revealed that the MEK inhibitor PD98059 inhibited breast cancer cell proliferation but contributed to increased migration ability, explained by increased levels of β-catenin levels in the nucleus [30]. Here, MAP2K7 is linked to breast carcinoma.